Basel, Switzerland

Lisha Wang

This inventor holds 36 USPTO granted patents and 7 published patent applications and 24 EPO patents, primarily in Virus Infection Treatment. Top assignees: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha, F. Hoffmann-La Roche Ag. Active years: 2013-2023.

USPTO Granted Patents = 36 

% Patents Active = 75.0

 

Average Co-Inventor Count = 6.4

ph-index = 5

Forward Citations = 105(Granted Patents)


Location History:

  • Basel, CH (2016 - 2021)
  • Riehen, CH (2016 - 2021)
  • Shanghai, CN (2013 - 2023)

Company Filing History:


Years Active: 2013-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
Respiratory Syncytial Virus
Aminothiazolopyrimidinediones
Benzazepine Compounds
Dihydropyrimidinyl
Aza-Oxo-Indoles
Pyrazolyl Compounds
Heteroaryldihydropyrimidines
Imidazoles
Dihydroquinoline
Carboxamide Compounds
Secondary Amide
Tertiary Amide
36 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Lisha Wang

Introduction: Inventor Lisha Wang, a visionary based in Basel, Switzerland, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Lisha Wang's recent patents include cutting-edge advancements in artificial intelligence, renewable energy solutions, and sustainable transportation methods.

Career Highlights: With a career spanning over two decades, Lisha Wang has established himself as a pioneer in the tech industry, leading research and development teams to create revolutionary products that have reshaped the way we live and work.

Collaborations: Throughout his career, Lisha Wang has collaborated with top research institutions, leading companies, and brilliant minds from around the world, fostering a culture of innovation and excellence.

Conclusion: Lisha Wang's relentless pursuit of innovation and his passion for creating a better future through technology continue to inspire generations of inventors and entrepreneurs worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…